摘要
到目前为止,开发用于细胞内应用的治疗肽的努力受到未修饰的线性肽高度不稳定的认识的指导,因此需要进行结构修饰以减少蛋白水解分解。大多数情况下,这个概念是迄今为止关于细胞内肽的大多数研究集中在抗原加工背景下的肽降解而不是肽稳定性的事实。有趣的是,在细胞内,缺乏任何化学修饰以增强稳定性的内源肽逃避降解,甚至可能调节细胞内信号通路。此外,许多未修饰的合成肽被设计成干扰细胞内信号传导,在引入细胞后,具有预期的活性,表明可以达到生物相关的浓度。本综述概述了与线性未修饰肽的探索和应用相关的结果和技术。引入细胞内肽周转后,综述提及合成肽作为细胞内信号传导调节剂的实例
关键词: 合成肽,细胞内肽,生物活性内源肽,肽稳定性,细胞内信号传导,肽递送。
Current Medicinal Chemistry
Title:Linear Peptides in Intracellular Applications
Volume: 24 Issue: 17
关键词: 合成肽,细胞内肽,生物活性内源肽,肽稳定性,细胞内信号传导,肽递送。
摘要: To this point, efforts to develop therapeutic peptides for intracellular applications were guided by the perception that unmodified linear peptides are highly unstable and therefore structural modifications are required to reduce proteolytic breakdown. Largely, this concept is a consequence of the fact that most research on intracellular peptides hitherto has focused on peptide degradation in the context of antigen processing, rather than on peptide stability. Interestingly, inside cells, endogenous peptides lacking any chemical modifications to enhance stability escape degradation to the point that they may even modulate intracellular signaling pathways. In addition, many unmodified synthetic peptides designed to interfere with intracellular signaling, following introduction into cells, have the expected activity demonstrating that biologically relevant concentrations can be reached. This review provides an overview of results and techniques relating to the exploration and application of linear, unmodified peptides. After an introduction to intracellular peptide turnover, the review mentions examples for synthetic peptides as modulators of intracellular signaling, introduces endogenous peptides with bioactivity, techniques to measure peptide stability, and peptide delivery. Future experiments should elucidate the rules needed to predict promising peptide candidates.
Export Options
About this article
Cite this article as:
Linear Peptides in Intracellular Applications, Current Medicinal Chemistry 2017; 24 (17) . https://dx.doi.org/10.2174/0929867324666170508143523
DOI https://dx.doi.org/10.2174/0929867324666170508143523 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued) Inhibition of V-ATPase and Carbonic Anhydrases as Interference Strategy with Tumor Acidification Processes
Current Pharmaceutical Design Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin
Current Pharmaceutical Design Personalized Peptide-based Vaccination for Treatment of Colorectal Cancer: Rational and Progress
Current Drug Targets Mining the Dark Matter of the Cancer Proteome for Novel Biomarkers
Current Cancer Therapy Reviews Simple and Convenient Synthesis of (±)-Bakuchiol
Letters in Organic Chemistry Radiolabelled Regulatory Peptides for Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Hardware and Software Approaches to Multi-Modality Imaging
Current Medical Imaging Inhibition of mTOR Signaling by Quercetin in Cancer Treatment and Prevention
Anti-Cancer Agents in Medicinal Chemistry Notch-Associated MicroRNAs in Cancer
Current Drug Targets From Nonsteroidal Aromatase Inhibitors to Multifunctional Drug Candidates: Classic and Innovative Strategies for the Treatment of Breast Cancer
Current Topics in Medicinal Chemistry Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Anaplastic Lymphoma Kinase Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Advances and Perspectives in Cancer Nanotherapy: The Added- Value of Nanocarriers
Current Nanomedicine Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Formulation and Stability Aspects of Nanosized Solid Drug Delivery Systems
Current Pharmaceutical Design Recent Advances in Minimal Access Surgery for Infants and Children
Current Pediatric Reviews